Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok1. fázis

Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study

A legfontosabb adatok

Ki végzi
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Hol
West Haven (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
1. fázis
Résztvevők
10 fő, tervezett
Kezdés
2025. júl. 28.
Várható befejezés
2027. ápr. 30.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
  • Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg
A regiszteradat frissítve
2026. szeptember 21.

Ki vehet részt

Életkor
21 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • Veterans and non-Veterans, ages 21 to 65
  • Able to read and write in English and sign the informed consent
  • Willing to comply with all study procedures and be available for the duration of the study
  • ECG that demonstrates no clinically significant conduction issues or arrhythmias
  • Have no clinically significant contraindications, in the judgement of the PI/study physician, for study participation (based on self-reported medical history and brief physical examination)
  • Have a current diagnosis of Alcohol use disorder (AUD) (mild, moderate, or severe) as determined by MINI-5
  • Have a lifetime traumatic event in their lifetime that meets Criterion A for PTSD as determined by screening interview and the MINI-5
  • Have a PCL-5 score > 15 prior to starting the study medication
  • Must have > 1 heavy drinking episodes (>4 standard drink units (SDU) for men; >3 SDU for women) in the last 30 days (assessed by the Timeline Follow Back (TLFB))
  • Females of childbearing potential (not surgically sterilized (tubal ligation/hysterectomy) or not post-menopausal (no menstrual period for > 6 months)) must be willing to use a medically acceptable and effective birth control method for 1 month before the study and while participating in the study. Medically acceptable methods of contraception that may be used by the participant include abstinence, birth control pills or patches, birth control implants, diaphragm, intrauterine device (IUD), or condoms

Ki nem vehet részt

  • Currently taking the following medications: a) medications for alcoholism (e.g. naltrexone, disulfiram, topiramate, acamprosate); b) psychotropic medications that promote sedation including sedative/hypnotics, barbiturates, antihistamines, sedative antidepressants (e.g. doxepin, mirtazapine, trazodone), and triptans (e.g., sumatriptan); c) antihypertensive medications; d) alpha-2-adrenergic agonists (clonidine, guanfacine, lofexidine); or adrenergic agents prescribed for other reasons are excluded (prazosin). (Permitted Concomitant Medications: The concomitant medications allowed in the study include non-sedative antidepressants used to treat PTSD)
  • Participation in a clinical trial of a pharmacological agent within 30 days prior to screening
  • Current bipolar disorder or psychotic disorders as determined by MINI-5
  • Current diagnosis of a substance use disorder (other than alcohol, nicotine, or marijuana) as determined by MINI-5
  • Recent history of complicated alcohol withdrawal, alcohol withdrawal seizures, or delirium tremens (DTs)
  • History of major medical illnesses including liver disease, heart disease, chronic pain or other medical conditions that the physician investigator deems contraindicated for the participant to be in the study
  • History of allergic reactions to dexmedetomidine or known allergy to dexmedetomidine
  • Clinically significant history of cardiac disease including (a) chronic hypertension (even if adequately controlled by antihypertensive medications); (b) history of syncope or other syncopal attacks; (c) current evidence of orthostatic hypotension (defined as a decrease in systolic BP of 20 mm Hg or decrease in diastolic BP of 10mm Hg within 3 minutes); (d) resting heart rate of <55 beats per minute; (e) systolic blood pressure <110mmHg or diastolic BP <70mmHg; or (f) participants with a QTC interval >440msec (males) or >460msec (females)
  • Clinically significant medical conditions including hepatic (ascites, bilirubin >10% above the upper limit of normal [ULN] or liver function tests [LFT] >3 × ULN)
  • Renal impairment as measured by BUN/Creatinine
  • Females who are pregnant, nursing, or planning to become pregnant during study participation
  • Current physiological alcohol dependence requiring a higher level of care (e.g., detox) as determined by study physician conducting physical examination and CIWA score. Tolerance to alcohol will be allowed
  • Score > 4 on Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar) at screening
  • Any finding that, in the view of the principal investigator, would compromise the subject's ability to fulfill the study visit schedule or requirements

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 21 és 65 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • VA Connecticut Healthcare SystemWest Haven, Egyesült ÁllamokContact: Jenelle Newcomb, BARésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The overall objective of the proposed study is to determine if Dexmedetomidine HCl (BXCL501) is safe for treatment of alcohol use disorder (AUD) with comorbid posttraumatic stress disorder (PTSD) in an outpatient setting and also shows potential signals of efficacy thereby supporting the conduct of later phase clinical trials.

A vizsgálat csoportja

  • BXCL501 Dose Range 40µg to 160µgEgyéb csoport

    Participants will receive 40µg on days 1-2. On days 3 and 4, participants will receive 40µg twice per day. On days 5 and 6 participants will receive 40µg in the morning and 80µg in the evening. On days 7-28 participants will receive 80µg in the morning and evening. Dose escalation will follow the above schedule based on tolerability assessed by clinician.

    Kezelés: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg és Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) on Ethanol in Heavy Drinkers With PTSD - Outpatient Study
Kérdések a feltételekről
Forrás: NCT06335407: ki vehet részt
A regiszteradat frissítve
2026. szeptember 21.